Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sh-OGT is a short hairpin RNA (shRNA) designed to genetically silence the expression of O-GlcNAc transferase (OGT). OGT is an enzyme that catalyzes O-GlcNAcylation, a post-translational modification that is frequently elevated in various malignancies, including prostate cancer. By targeting OGT mRNA for degradation, sh-OGT reduces the levels of O-GlcNAcylated proteins, which in turn inhibits tumor cell proliferation and enhances the sensitivity of cancer cells to chemotherapeutic agents such as docetaxel. This approach targets the miR-140/OGT signaling axis, offering a potential adjuvant strategy to overcome drug resistance in prostate cancer treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sh-OGT.